CD274 and melanoma: Our stage III melanoma patients don’t show an enhanced inflammatory profile, and for this reason may be able to keep an active and stable response while some patients with metastatic spread seem to have an already solicited immune system (Figure 3A; patients’ clusters 5 and 6) that probably could not keep immune surveillance for a long duration after triggering by anti-PD-1/anti-PD-L1 ICIs.